Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0

Journal of Gene Medicine

Volumn 10, Issue 2, 2008, Pages 152-164

  Burris, Clark A ^a   de Silva, Suresh ^a   Narrow, Wade C ^a   Casey, Ann E ^a   Lotta Jr , Louis T ^a   Federoff, Howard J ^a,b   Bowers, William J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bacterial artificial chromosome; Gene transfer; Helper virus free packaging; HMBA; HSV amplicon; ICP0

Indexed keywords

CELL PROTEIN; HERPESVIRUS VECTOR; HEXAMETHYLENEBISACETAMIDE;

AMPLICON; ANIMAL CELL; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE REPLICATION; GENE TRANSFER; GENETIC TRANSDUCTION; HELPER VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS PARTICLE; VIRUS TITRATION;

ACETAMIDES; ANIMALS; CELL NUCLEUS STRUCTURES; CERCOPITHECUS AETHIOPS; GENE EXPRESSION REGULATION, VIRAL; HELPER VIRUSES; HERPESVIRUS 1, HUMAN; IMMEDIATE-EARLY PROTEINS; MICE; NIH 3T3 CELLS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES; VERO CELLS; VIRION; VIRUS ASSEMBLY;

BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 39449090733     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1130     Document Type: Article

References (50)

1. Wade-Martins R, Smith ER, Tyminski E, et al. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001; 19: 1067-1070.
2. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 305-310.
3. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
4. Geschwind MD, Hartnick CJ, Liu W, et al. Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. Hum Gene Ther 1996; 7: 173-182.
5. Kaplitt MG, Kwong AD, Kleopoulos SP, et al. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA 1994; 91: 8979-8983.
6. Lu B, Federoff HJ. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum Gene Ther 1995; 6: 421-430.
7. Geschwind MD, Lu B, Federoff HJ. Expression of neurotrophic genes from herpes simplex virus type 1 vectors: modifying neuronal phenotype. Methods Neurosci 1994; 21: 462-482.
8. Bowers WJ, Howard DF, Brooks AI, et al. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Ther 2001; 8: 111-120.
9. Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
10. Saeki Y, Fraefel C, Ichikawa T, et al. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
11. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998; 72: 7137-7143.
12. Detrait ER, Bowers WJ, Halterman MW, et al. Reporter gene transfer induces apoptosis in primary cortical neurons. Mol Ther 2002; 5: 723-730.
13. Olschowka JA, Bowers WJ, Hurley SD, et al. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol Ther 2003; 7: 218-227.
14. Sun M, Lee J, Yu L, et al. Modest increases in the titers of helper virus-free herpes simplex virus 1 (HSV-1) vectors by packaging in a cell line with inducible expression of HSV-1 VP16 or by treatment with N,N′-hexamethylene-bis-acetamide. Acta Virol 2000; 44: 365-369.
15. Smiley JR, Duncan J. Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 produces a phenotype similar to that of the in1814 linker insertion mutation. J Virol 1997; 71: 6191-6193.
16. Klichko V, Archin N, Kaur R, et al. Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol 2006; 80: 4570-4579.
17. Yang WC, Devi-Rao GV, Ghazal P, et al. General and specific alterations in programming of global viral gene expression during infection by VP16 activation-deficient mutants of herpes simplex virus type 1. J Virol 2002; 76: 12758-12774.
18. Poon AP, Gu H, Roizman B. ICPO and the US3 protein kinase of herpes simplex virus 1 independently block histone deacetylation to enable gene expression. Proc Natl Acad Sci USA 2006; 103: 9993-9998.
19. Lomonte P, Thomas J, Texier P, et al. Functional interaction between class II histone deacetylases and ICPO of herpes simplex virus type 1. J Virol 2004; 78: 6744-6757.
20. Gu H, Liang Y, Mandel G, et al. Components of the REST/CoREST/ histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells. Proc Natl Acad Sci U S A 2005; 102: 7571-7576.
21. Desai P, Ramakrishnan R, Lin ZW, et al. The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICPO during infection. J Virol 1993; 67: 6125-6135.
22. Hagglund R, Roizman B. Role of ICPO in the strategy of conquest of the host cell by herpes simplex virus 1. J Virol 2004; 78: 2169-2178.
23. Bowers WJ, Howard DF, Federoff HJ. Discordance between expression and genome transfer titering of HSV amplicon vectors: recommendation for standardized enumeration. Mol Ther 2000; 1: 294-299.
24. Everett RD, Cross A, Orr A. A truncated form of herpes simplex virus type 1 immediate-early protein Vmw110 is expressed in a cell type dependent manner. Virology 1993; 197: 751-756.
25. Santos Y, Simon DA, Conway E, et al. Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther 2007; 18: 93-105.
26. Everett RD, Boutell C, Orr A. Phenotype of a herpes simplex virus type 1 mutant that fails to express immediate-early regulatory protein ICPO. J Virol 2004; 78: 1763-1774.
27. Dargan DJ, Subak-Sharpe JH. The effect of herpes simplex virus type 1 L-particles on virus entry, replication, and the infectivity of naked herpesvirus DNA. Virology 1997; 239: 378-388.
28. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
29. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICPO affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71: 4614-4625.
30. Eidson KM, Hobbs WE, Manning BJ, et al. Expression of herpes simplex virus ICPO inhibits the induction of interferon-stimulated genes by viral infection. J Virol 2002; 76: 2180-2191.
31. Hobbs WE, 2nd, DeLuca NA. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICPO. J Virol 1999; 73: 8245-8255.
32. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol 2000; 2: E85-90.
33. Everett RD. ICPO, a regulator of herpes simplex virus during lytic and latent infection. Bioessays 2000; 22: 761-770.
34. Mossman KL, Macgregor PF, Rozmus JJ, et al. Herpes simplex virus triggers and then disarms a host antiviral response. J Virol 2001; 75: 750-758.
35. Poppers J, Mulvey M, Khoo D, et al. Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000; 74: 11215-11221.
36. 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1a to dephosphorylate the a subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843-848.
37. Lubinski JM, Wang L, Soulika AM, et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998; 72: 8257-8263.
38. Weeks BS, Sundaresan P, Nagashunmugam T, et al. The herpes simplex virus-1 glycoprotein E (gE) mediates IgG binding and cell-to-cell spread through distinct gE domains. Biochem Biophys Res Commun 1997; 235: 31-35.
39. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415-418.
40. Hill AB, Barnett BC, McMichael AJ, et al. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 22: 2736-2741.
41. Jin BK, Belloni M, Conti B, et al. Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum Gene Ther 1996; 7: 2015-2024.
42. EverettRD, Maul GG. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J 1994; 13: 5062-5069.
43. Maul GG, Everett RD. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICPO. J Gen Virol 1994; 75: 1223-1233.
44. Suzuki M, Kasai Y, Saeki Y. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol 2006; 80: 3293-3300.
45. Marks PA, Richon VM, Kiyokawa H, et al. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci U S A 1994; 91: 10251-10254.
46. Egorin MJ, Sigman LM, Van Echo DA, et al. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res 1987; 47: 617-623.
47. Young CW, Fanucchi MP, Declan Walsh T, et al. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res 1988; 48: 7304-7309.
48. Kitagawa R, Hagihara K, Uhara M, et al. Inhibitory effect of hexamethylene bisacetamide on replication of human cytomegalovirus. Arch Virol 2005; 150: 1977-1991.
49. Elliott G, Hafezi W, Whiteley A, et al. Deletion of the herpes simplex virus VP22-encoding gene (UL49) alters the expression, localization, and virion incorporation of ICPO. J Virol 2005; 79: 9735-9745.
50. Block GJ, Eskiw CH, Dellaire G, et al. Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies. Mol Cell Biol 2006; 26: 8814-8825.